Related Experiment Video
Updated: Aug 4, 2026
Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models
Published on: August 9, 2012
New pharmacologic targets for the treatment of the overactive bladder: an update
1Department of Clinical Pharmacology, Lund University Hospital, Lund, Sweden. Karl-Erik.Andersson@klinfarm.lu.se
Abstract:
Although currently available antimuscarinic agents are the standard of care for overactive bladder (OAB), they are limited by certain side effects, particularly dry mouth and constipation. Research aimed at discovering new therapies for OAB has resulted in the identification of some promising drugs. Investigations of pharmacologic targets in the central nervous system (CNS) have yielded encouraging results with several agents, including tramadol and gabapentin. Further investigation may show that drugs acting at serotonergic and noradrenergic CNS sites are clinically useful as therapies for OAB. Some peripherally acting drugs, such as resiniferatoxin and botulinum toxin, have already been proved to be of clinical value. However, development of other agents that block afferent or efferent nerve impulses in the bladder through activity at vanilloid, purinergic, or opioid-like receptor sites may result in clinically useful drugs.
Insights
New overactive bladder (OAB) therapies are being explored beyond current antimuscarinic agents due to side effects. Promising central and peripheral nervous system drug targets are under investigation for improved OAB treatment.
Area of Science:
- Pharmacology
- Urology
- Neuroscience
Background:
- Current overactive bladder (OAB) treatments, primarily antimuscarinic agents, are limited by side effects like dry mouth and constipation.
- Research is actively seeking novel therapeutic strategies to manage OAB symptoms effectively.
Purpose of the Study:
- To review emerging pharmacologic targets and agents for overactive bladder (OAB) treatment.
- To explore both central nervous system (CNS) and peripheral targets for novel OAB therapies.
Main Methods:
- Review of current literature on OAB pharmacotherapy.
- Analysis of investigational drugs targeting CNS pathways (serotonergic, noradrenergic) and peripheral mechanisms (vanilloid, purinergic, opioid receptors).
Main Results:
- Central nervous system agents like tramadol and gabapentin show promise.
- Peripherally acting drugs such as resiniferatoxin and botulinum toxin are clinically valuable.
- Novel agents targeting bladder receptor sites offer potential for future OAB management.
Conclusions:
- Investigational drugs targeting CNS and peripheral pathways represent a promising future for overactive bladder (OAB) treatment.
- Further research into novel receptor targets may yield more effective and tolerable OAB therapies.
Related Concept Videos
01:26Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:19Anatomy of the Genitourinary System II: Bladder and Urethra
01:30Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
01:30Urinary Tract Calculi III: Medical Management
01:19Urodynamic Studies: Uroflowmetry